{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T22:01:39Z","timestamp":1766268099341},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,1,7]],"date-time":"2014-01-07T00:00:00Z","timestamp":1389052800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s11883-013-0385-x","type":"journal-article","created":{"date-parts":[[2014,1,6]],"date-time":"2014-01-06T05:16:14Z","timestamp":1388985374000},"source":"Crossref","is-referenced-by-count":10,"title":["Treatment of Cholesterol in the Elderly: Statins and Beyond"],"prefix":"10.1007","volume":"16","author":[{"given":"John C.","family":"LaRosa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,1,7]]},"reference":[{"key":"385_CR1","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","volume":"360","author":"J Shepherd","year":"2002","unstructured":"Shepherd J, Blauw G, Murphy M, Ethan, et al. Pravastatin in Elderly Individuals at Risk of Vascular Disease (PROSPER): a randomized controlled trial. Lancet. 2002;360:1623\u201330.","journal-title":"Lancet"},{"key":"385_CR2","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1001\/jama.282.24.2340","volume":"282","author":"J LaRosa","year":"1999","unstructured":"LaRosa J, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999;282:2340\u20136.","journal-title":"JAMA"},{"issue":"4","key":"385_CR3","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.amjcard.2006.08.063","volume":"99","author":"S Kamai-Bahl","year":"2007","unstructured":"Kamai-Bahl S, Burker T, Watson D, Wentworth C. Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice. Am J Cardiol. 2007;99(4):530\u20134.","journal-title":"Am J Cardiol"},{"key":"385_CR4","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1161\/CIRCOUTCOMES.111.000071","volume":"6","author":"N Huseyn","year":"2013","unstructured":"Huseyn N, Jasper B, Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246,955 participants from 135 randomized controlled trials. Circ Cardiovasc Qual Outcomes. 2013;6:390\u20139. doi: 10.1161\/CIRCOUTCOMES.111.000071 .","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"3","key":"385_CR5","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2165\/00002018-200528030-00007","volume":"28","author":"A R\u00e4tz-Bravo","year":"2005","unstructured":"R\u00e4tz-Bravo A, Tchambaz L, Kr\u00e4henb\u00fchl-Melcher A, et al. Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidemias receiving HMG-CoA reductase inhibitor therapy. Drug Saf. 2005;28(3):263\u201375.","journal-title":"Drug Saf"},{"key":"385_CR6","doi-asserted-by":"crossref","first-page":"526","DOI":"10.7326\/0003-4819-158-7-201304020-00004","volume":"158","author":"H Zhang","year":"2013","unstructured":"Zhang H, Plutzky J, Skentos H, et al. Discontinuation of statins in routine care settings. Ann Intern Med. 2013;158:526\u201334.","journal-title":"Ann Intern Med"},{"key":"385_CR7","doi-asserted-by":"crossref","first-page":"f2610","DOI":"10.1136\/bmj.f2610","volume":"346","author":"A Carter","year":"2013","unstructured":"Carter A, Gomes T, Camacho X, et al. Risk of incident diabetes among patients treated with statins: population based study. BMJ. 2013;346:f2610. doi: 10.1136\/BMJ.f2610 .","journal-title":"BMJ"},{"key":"385_CR8","doi-asserted-by":"crossref","unstructured":"Axsom K, Berger J, Schartzbard A. Statins and diabetes: the good, the bad, and the unknown. Curr Atherscler Rep. 2013; 299. doi: 10.1007\/s11883-012-0299-z .","DOI":"10.1007\/s11883-012-0299-z"},{"issue":"3","key":"385_CR9","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1161\/CIRCOUTCOMES.111.000015","volume":"6","author":"D Ko","year":"2013","unstructured":"Ko D, Wijeysundera H, Jackevicius CA, et al. Diabetes mellitus and cardiovascular events in older patients with myocardial infarction prescribed intensive-dose and moderate-dose statins. Circ Cardiovasc Qual Outcomes. 2013;6(3):315\u201322.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"385_CR10","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jacc.2007.06.063","volume":"51","author":"J Afilalo","year":"2008","unstructured":"Afilalo J, Duque G, Steele R, et al. Statins for secondary prevention in elderly patients. J Am Coll Cardiol. 2008;51:37\u201345.","journal-title":"J Am Coll Cardiol"},{"key":"385_CR11","unstructured":"US Food and Drug Administration. FDA drug safety communication: important safety label changes to cholesterol-lowering statin drugs. http:\/\/www.fda.gov\/drugs\/drugsafety\/ucm293101.htm (2012)."},{"issue":"12","key":"385_CR12","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1345\/aph.1K280","volume":"41","author":"NN Henyan","year":"2007","unstructured":"Henyan NN, Riche D, East HE, Gann P. Impact of statins on risk of stroke: a meta-analysis. Ann Pharmacother. 2007;41(12):1937\u201345.","journal-title":"Ann Pharmacother"},{"key":"385_CR13","first-page":"49","volume-title":"Practical management of lipid disorders","author":"H Ginsberg","year":"1992","unstructured":"Ginsberg H. Niacin. In: LaRosa J, editor. Practical management of lipid disorders. Fort Lee: Health Care Communications; 1992. p. 49\u201359."},{"key":"385_CR14","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0735-1097(86)80293-5","volume":"8","author":"P Canner","year":"1986","unstructured":"Canner P, Berge K, Wenger N, et al. Fifteen Year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:287\u201394.","journal-title":"J Am Coll Cardiol"},{"key":"385_CR15","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1001\/jama.1987.03390230069027","volume":"257","author":"D Blankenhorn","year":"1987","unstructured":"Blankenhorn D, Nessin S, Johnson R, et al. Beneficial effects of combined colestipol-niacin on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233\u201340.","journal-title":"JAMA"},{"issue":"19","key":"385_CR16","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJM199011083231901","volume":"323","author":"B Brown","year":"1990","unstructured":"Brown B, Albers J, Fisher L, et al. Regression of coronary artery disease as a result of intensive lipid lowering in men with high levels of apolipoprotein B. N Engl J Med. 1990;323(19):1289\u201398.","journal-title":"N Engl J Med"},{"issue":"22","key":"385_CR17","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","volume":"345","author":"B Brown","year":"2001","unstructured":"Brown B, Zhao X, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention for coronary disease. N Engl J Med. 2001;345(22):1583\u201392.","journal-title":"N Engl J Med"},{"key":"385_CR18","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","volume":"365","author":"The AIM-HIGH Investigators","year":"2011","unstructured":"The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255\u201367.","journal-title":"N Engl J Med"},{"key":"385_CR19","unstructured":"Armitage J. Results of the HPS2-THRIVE study. Paper presented at: American College of Cardiology meeting, March 2013."},{"key":"385_CR20","first-page":"37","volume-title":"Practical management of lipid disorders","author":"D Gordon","year":"1992","unstructured":"Gordon D. Bile acid sequestrants. In: LaRosa J, editor. Practical management of lipid disorders. Fort Lee: Health Care Communications; 1992. p. 37\u201348."},{"key":"385_CR21","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.1984.03340270029025","volume":"251","author":"Lipid Research Clinics Program","year":"1984","unstructured":"Lipid Research Clinics Program. The Lipid Research Clinics coronary primary prevention results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251:351\u201364.","journal-title":"JAMA"},{"issue":"5","key":"385_CR22","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2165\/11599290-000000000-00000","volume":"29","author":"J Marrs","year":"2012","unstructured":"Marrs J. Glucose and low-density lipoprotein cholesterol lowering in elderly patients with type 2 diabetes: focus on combination therapy with colesevelam HCl. Drugs Aging. 2012;29(5):e1\u201312.","journal-title":"Drugs Aging"},{"key":"385_CR23","first-page":"61","volume-title":"Practical management of lipid disorders","author":"WV Brown","year":"1992","unstructured":"Brown WV. The fibric acid derivatives. In: LaRosa J, editor. Practical management of lipid disorders. Fort Lee: Health Care Communications; 1992. p. 61\u201374."},{"issue":"9729","key":"385_CR24","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/S0140-6736(10)60656-3","volume":"375","author":"M Jun","year":"2010","unstructured":"Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010;375(9729):1875\u201384.","journal-title":"Lancet"},{"key":"385_CR25","first-page":"415","volume":"8","author":"A Binh","year":"2012","unstructured":"Binh A, Dayspring T, Toth P. Ezitimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag. 2012;8:415\u201327.","journal-title":"Vasc Health Risk Manag"},{"key":"385_CR26","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/MOL.0b013e32833c1f16","volume":"21","author":"J Guyton","year":"2010","unstructured":"Guyton J. Combination regimens with statin, niacin and intestinally active LDL-lowering drugs: alternatives to statins? Curr Opin Lipidol. 2010;21:372\u20137.","journal-title":"Curr Opin Lipidol"},{"key":"385_CR27","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa0804602","volume":"359","author":"AB Rosseb\u00f8","year":"2008","unstructured":"Rosseb\u00f8 AB, Pedersen TR, Boman B, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343\u201356.","journal-title":"N Engl J Med"},{"key":"385_CR28","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1212914","volume":"369","author":"The Look Ahead Research Group","year":"2013","unstructured":"The Look Ahead Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369:145\u201354.","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"385_CR29","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.jacl.2013.02.004","volume":"7","author":"P Toth","year":"2013","unstructured":"Toth P. Emerging LDL, therapies: mimoperson-antisense oligonucleotide therapy in the management of hypercholesterolemia. J Clin Lipidol. 2013;7(Suppl):S6\u201310.","journal-title":"J Clin Lipidol"},{"issue":"Suppl","key":"385_CR30","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.jacl.2013.03.003","volume":"7","author":"A Goldberg","year":"2013","unstructured":"Goldberg A. Emerging low density lipoprotein therapies: microsomal triglyceride transfer protein inhibitors. J Clin Lipidol. 2013;7(Suppl):S16\u201320.","journal-title":"J Clin Lipidol"},{"issue":"Suppl","key":"385_CR31","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.jacl.2013.03.004","volume":"7","author":"M Davidson","year":"2013","unstructured":"Davidson M. Emerging low-density lipoprotein therapies: targeting PCSK9 for low-density lipoprotein reduction. J Clin Lipidol. 2013;7(Suppl):S11\u20136.","journal-title":"J Clin Lipidol"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-013-0385-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11883-013-0385-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-013-0385-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T19:49:08Z","timestamp":1559418548000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11883-013-0385-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,7]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["385"],"URL":"https:\/\/doi.org\/10.1007\/s11883-013-0385-x","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,7]]},"article-number":"385"}}